Navigation Links
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
Date:9/9/2008

severe pain due to osteoarthritis of the hip or knee. After a screening and washout period from previous treatments (less than or equal to 14 days), patients were administered two periods of treatment with study drugs. Patients were first titrated to effective pain management levels with ALO-01 capsules during open label titration, they were then randomized to double-blind treatment with either ALO-01 capsules or placebo for 12 weeks. Study participants were allowed to use acetaminophen as a rescue medication, up to 500 mg every six hours, as needed.

Efficacy assessments included pain intensity scores on the BPI, recorded in a subject diary and assessed at in-clinic visits.

Safety and tolerability included measurements by rates of self-reported adverse events and a measure of opioid withdrawal, an indication of naltrexone leakage from the capsules, called clinical opiate withdrawal scores (COWS). ALO-01 capsules were safe and well-tolerated in this study, with an overall safety profile consistent with that of other opioid products. COWS data suggest that naltrexone did not leak out of the capsules, and there was no increased risk of opioid withdrawal versus placebo. Adverse events were mostly mild to moderate. The most common adverse events during titration with ALO-01 were constipation (30.5 percent) and nausea (21.0 percent); during the 12-week maintenance phase the adverse events were diarrhea (12.3 percent and 12.1 percent) and nausea (11.7 percent and 7.5 percent) for ALO-01 and placebo groups, respectively.

Forward-Looking Statements

Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other important potential risks
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 Today, the National ... ® ) issued a report urging greater accountability ... is taken against websites illegally selling medications online. ... Outlet Identification Program Progress Report for State and ... thousands of websites illegally distribute medications and avoid ...
(Date:7/31/2015)... 31, 2015 According to a new ... Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite ... Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, The ... Billion by 2020, at a CAGR of 7.6%.from 2015 to ... market data T ables and 37 ...
(Date:7/31/2015)... 31, 2015  Semler Scientific, Inc. (Nasdaq: SMLR ... to healthcare insurers and physician groups, today reported financial ... "In the second quarter of 2015, ... growth of 54%, quarter over quarter revenue growth of ... base of FloChec® units of 18%," said Doug Murphy-Chutorian, ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
...  Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing ... that the United States Food and Drug Administration ... treatment of Duchenne muscular dystrophy (DMD). DMD is ... approximately 1 in 3,500 boys worldwide. HT-100, also ...
... 4, 2012  Elevation Pharmaceuticals, Inc. announced today the closing ... investor Novo Ventures , to fund development of Elevation,s ... disease (COPD). All previous investors participated in the round, including ... Capital and Mesa Verde Venture Partners . In ...
Cached Medicine Technology:Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 2Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 3Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 2Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 3
(Date:8/1/2015)... ... August 02, 2015 , ... Back packs can be dangerous? ... however, back packs can wreck havoc on a kid's spine. With school starting again, ... and from school. Make sure you are aware of how to help them prevent ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Calvary Hospital today ... housed at their Bronx campus. The goal is to bring this Torah – dating ... used in Jewish rituals and religious services. , Scroll No. 515, from the ...
(Date:8/1/2015)... York, NY (PRWEB) , ... August 01, 2015 , ... ... Vine cyberespionage group , who are thought to have been behind the attack on ... the topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil Valentine ... mile trek of the Appalachian Trail by stepping off Springer Mountain and heading ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
Breaking Medicine News(10 mins):Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... Anthony Movshon, director of New York University,s Center for ... 2010 Antnio Champalimaud Vision Award for his work on ... announced today. Movshon shares the award with William T. ... Vision Award comes with a $1.3 million prize, the ...
... is examining a sequence of DNA- known as telomeres - ... that these structures shrink in length over an individual,s lifetime ... commonly associated with ageing and, perhaps most importantly, the development ... how this process is controlled. Jonathan Williams, from the ...
... club, they gain a stronger sense of who they are ... The study suggests that even small improvements in self ... trouble. "The more kids participate in these clubs, the ... professor of social work at Ohio State. "And then that ...
... Structural Genomics Consortium (SGC) and Pfizer today announced that ... small molecule inhibitors "chemical probes" for proteins ... are now members of this collaboration, launched in late ... high quality research reagents, free from restriction on use. ...
... 2010 -- The 5th ESU Master class on medical treatment ... Urology (ESU) on 25-27 June 2010 at the Barcel Hotel ... prime venue to scrutinise current practices and survey the latest ... medical disciplines involved in cancer therapy. It is open to ...
... the open access option for participating journals fell to 5.9%, compared ... uptake amongst 11 new titles joining Oxford Open in 2009. On ... entered the scheme prior to 2008 was stable (6.7%, compared with ... Oxford Open prior to 2008, by broad subject area the highest ...
Cached Medicine News:Health News:NYU's Movshon receives Champalimaud Vision Award for work on how brain reconstructs images 2Health News:Size matters -- when it comes to DNA 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 2Health News:Youth clubs strengthen kids' self image to keep them out of trouble 3Health News:Pfizer joins open-access medicinal chemistry public-private collaboration 2Health News:5th ESU Master Class on Medical Treatment for Urological Cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: